Renaissance Capital logo

Personalis Priced, Nasdaq: PSNL

Provides a genome sequencing platform for cancer drug development.

Industry: Health Care

Latest Trade: $18.86 0.00 (0.0%)

First Day Return: +67.6%

Return from IPO: +10.9%

Industry: Health Care

We are a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. We designed our NeXT Platform to adapt to the complex and evolving understanding of cancer, providing our biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover roughly 50 to 500 genes. We are also developing a complementary liquid biopsy assay that analyzes all human genes versus the more narrowly focused liquid biopsy assays that are currently available. By combining technological innovation, operational scale, and regulatory differentiation, our NeXT Platform is designed to help our customers obtain new insights into the mechanisms of response and resistance to therapy as well as new potential therapeutic targets. Our platform enhances the ability of biopharmaceutical companies to unlock the potential of conducting translational research in the clinic rather than with pre-clinical animal models or cancer cell lines. We are also planning to release a diagnostic based on our NeXT Platform that we envision being used initially by biopharmaceutical customers and clinical collaborators.
more less
IPO News for Personalis
more
IPO Data
IPO File Date 05/23/2019
Offer Price $17.00
Price Range $14.00 - $16.00
Offer Shares (mm) 7.9
Deal Size ($mm) $135
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/19/2019
Offer Price $17.00
Price Range $14.00 - $16.00
Offer Shares (mm) 7.9
Deal Size ($mm) $135
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Menlo Park, CA
Founded 2011
Employees 147
Website www.personalis.com